['acute hepatitis c', 'human immunodeficiency virus', 'hepatitis c']
['grazoprevir/elbasvir 100mg/50mg']

        Inclusion Criteria:

          1. HIV positive

          2. Acute HCV genotype 1 or 4 infection (≤26 weeks old at the baseline visit)

        Exclusion Criteria:

          1. Not on cART and a CD4 <500 at the time of screening

          2. Patients on cART for >6 months with a HIV viral load >400 copies

          3. Disallowed co-medication that cannot be stopped or replaced

          4. History of liver cirrhosis of any etiology. Inclusion of patients with a chronic
             well-controlled HBV (HBV-DNA <below the limit of detection) is allowed if fibroscan
             excludes >F1 fibrosis

          5. Protease inhibitor based and NNRTI based cART regimens are not allowed. Therefore, the
             inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse
             transcriptase inhibitors and an allowed third agent which can be raltegravir
             (Isentress®) 400mg BID, dolutegravir (Tivicay) 50mg QD or rilpivirine 25mg QD.
      